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model predicts that streptolydigin should trap NTP in
the pre-insertion site in such an elongation complex
structure. Additionally, this cocrystal would be of great
interest because it might reveal a specific role for the
trigger loop in nucleotide binding or insertion. Since it is
often disordered in RNAP crystal structures, the highly
flexible trigger loop has received less attention as a key
player in the nucleotide addition cycle. However, the
structural element most affected by streptolydigin is
this highly conserved loop (its position shifts by at least
11 Å upon streptolydigin binding), whose position in
apo-RNAP clashes extensively with bound streptolydi-
gin. Interestingly, Temiakov et al. report that deletion of
the trigger loop inhibits nucleotide addition more than
10,000-fold, but that the residual activity is actually
stimulated by streptolydigin binding. One wonders if
this hints at a direct role of the trigger loop in nucleotide
addition and in the mechanism of streptolydigin inhibi-
tion that remains underappreciated owing to its elusive
location in many RNAP structures.
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A Neuropeptide Courier
for -Opioid Receptors?
The -opioid receptor and the precursor protein of a
neuropeptide, substance P, are colocalized in the
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s
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t
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clarge dense-core vesicles of pain-sensing neurons. In
this issue of Cell, Guan et al. (2005) report that traf-
ficking of the -opioid receptor to these vesicles de-
pends on its physical interaction with the substance
P domain of its precursor polyprotein (protachykinin).
Moreover, in mice lacking this precursor, the contri-
bution of the -opioid receptor to pain processing is
dramatically altered. These observations suggest a
new role for peptide precursors as sorting signals in
vesicular transport.
In neurons, classic synaptic vesicles house small mole-
cule neurotransmitters, such as acetylcholine or gluta-
mate, and mediate rapid Ca2+-triggered release of neu-
rotransmitter packets into the synaptic cleft. Synaptic
vesicles spend their life at the nerve terminal where, in
response to depolarization, they undergo exocytosis
and are subsequently recycled from the plasma mem-
brane. Neurons also contain large dense-core vesicles
(LDCVs), which are Golgi-derived neuropeptide-rich
units that belong to the so-called “regulated” arm of
the protein secretory pathway (Arvan and Castle, 1998;
Kelly, 1985). In addition to mediating neuropeptide re-
lease, LDCVs shuttle cell-surface receptors to the pre-
synaptic plasmamembrane in response to an excitatory
stimulus. However, it is not clear how these receptors
are directed preferentially to LDCVs, rather than to the
ubiquitous or “constitutive” secretory pathway that car-
ries housekeeping proteins to the cell surface. In this
issue, Guan et al. (2005) provide tantalizing evidence
that this sorting is accomplished through specific in-
teractions between two constituents of the LDCV
cargo. They show that protachykinin, the precursor of
the neuropeptide substance P, binds to the G protein-
coupled δ-opioid receptor and regulates the trafficking
of this receptor in primary afferent neurons of the pain
pathway. Importantly, substance P is not considered to
be a physiological ligand for the δ-opioid receptor,
which is activated by endogenous opioid peptides,
such as enkephalin.
The critical observation in this study comes from the
analysis of mice lacking the preprotachykinin A (PPT-A)
gene, which encodes a polyprotein precursor that is
proteolytically processed to generate the neuropep-
tides, substance P and neurokinin A (Nawa et al., 1983).
When noxious stimuli activate sensory nerve endings
in the skin or other peripheral organs, LDCVs release
substance P from presynaptic terminals within the spi-
nal cord dorsal horn, leading to enhancement of noci-
ceptive (pain) signals and hypersensitivity to pain (Bas-
baum and Woolf, 1999) (see Figure 1). In addition to the
expected loss of substance P in PPT-A-deficient mice,
Guan et al. (2005) show that there is also a profound
edistribution of δ-opioid receptors from LDCVs to ve-
icular compartments characteristic of the constitutive
ecretory pathway.
But is there a functional or structural relationship be-
ween this G protein-coupled opioid receptor and the
ubstance P precursor that could explain this unex-
ected result? Guan et al. (2005) provide evidence from
istological, biochemical, and mutagenesis experiments
o support a new model in which a luminal-facing (ex-
racellular) loop of the δ-opioid receptor forms a physi-
al interaction with the substance P domain of PPT-A,
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497Figure 1. Cotrafficking of δ-Opioid Receptors
and Protachykinin A in Sensory-Nerve Ter-
minals of the “Pain Pathway”
Pain is generated when noxious stimuli ex-
cite pain-sensing nerve fibers triggering re-
lease of neurotransmitters at synapses
within the spinal cord dorsal horn (light blue).
These nerve terminals (red box) feature sev-
eral types of secretory vesicles. Classical
synaptic vesicles (yellow) contain small-
molecule neurotransmitters, such as gluta-
mate or ATP, whereas large dense-core vesi-
cles (LDCVs; blue) contain neuropeptides,
such as substance P. Following excitation of
pain-sensing neurons, large dense-core ves-
icles also shuttle membrane proteins, such
as the G protein-linked δ-opioid receptor
(green), to the cell surface. The δ-opioid re-
ceptor (DOR) apparently finds its way into
LDCVs by virtue of a physical interaction
with the substance P domain of the poly-
protein precursor, protachykinin A (PPT-A;
black curving line). In the absence of pro-
tachykinin A, δ-opioid receptors are redis-
tributed and may reach the plasma mem-
brane via a constitutive pathway of protein
secretion (red).presumably linking these molecules together as they
traverse the secretory pathway en route to the LDCV.
These observations indicate that prohormone precur-
sors do more than simply give rise to biologically active
peptides. They may also provide sorting signals for re-
ceptors or other membrane proteins destined for
LDCVs. Also, this model suggests how phenotypes re-
sulting from loss of ligand expression might differ from
those associated with loss of the cognate receptor
(Cao et al., 1998; De Felipe et al., 1998).
One surprising observation is that the interaction be-
tween the δ-opioid receptor and the PPT-A protein is
determined primarily by the substance P domain within
the precursor polypeptide. Whether the surrounding
precursor sequence contributes to or facilitates this in-
teraction, perhaps by presenting substance P to the
δ-opioid receptor in an efficient membrane-associated
configuration, is still not clear. The authors show that
radiolabeled mature substance P can bind to an extra-
cellular domain of the δ-opioid receptor (Guan et al.,
2005). Presumably, this interaction is of low affinity as
all specific binding of substance P in the central ner-
vous system is lost in mice that lack the substance P
receptor. Regardless, the structural underpinnings of
this peptide-receptor interaction, as well as measure-
ments of its strength and specificity, merit further analy-
sis. These issues may be important in considering
whether the mechanism proposed by Guan et al. de-
pends on the presence of highly concentrated material
within the LDCV, which would be reminiscent of aggre-
gation-based models of protein sorting (Kelly, 1985).
A key question addressed by Guan et al. (2005) con-
cerns the amount of δ-opioid receptor that is trans-
ported from the cell body to the synaptic terminals of
the pain-sensing neurons and the functional signifi-
cance of the trafficking of this receptor via either the
regulated LDCV or the constitutive secretory pathway.
The authors used immunocytochemistry to localize theδ-opioid receptor in the superficial dorsal horn of the
PPT-A mutant mice and found a very large decrease
in staining. On the other hand, there was only a small
decrease in binding of radiolabeled δ-opioid receptor
agonists in PPT-A mutant mice. Taken together, these
data indicate that in the absence of substance P, the
δ-opioid receptor is shunted to the constitutive secre-
tory pathway. However, the discrepancy between δ-opi-
oid receptor detection by immunostaining and radioli-
gand binding suggests that the contribution of the
constitutive pathway to plasma membrane δ-opioid re-
ceptors in wild-type as well as mutant mice may be
underestimated using immunocytochemistry. With re-
spect to the functional significance of the two path-
ways, Guan et al. show that intrathecal administration
(injection into the cerebrospinal fluid of the lumbar spi-
nal cord) of a selective δ-opioid receptor agonist pro-
duces a profound analgesia in a test of heat-evoked
pain. As the δ-opioid receptor is primarily expressed by
the primary afferent pain fibers, this analgesic action is
presumed to result from a presynaptic inhibition of Ca2+
channels mediated by the δ-opioid receptor (Acosta
and Lopez, 1999) and a resultant decrease in neuro-
transmitter release from the primary afferent terminal
onto spinal cord “pain”-transmission neurons. Because
the analgesic action of a δ-opioid receptor agonist
completely disappeared in PPT-A mutant mice, it fol-
lows that any plasma membrane expression of the
δ-opioid receptor that arises from the constitutive path-
way must be nonfunctional, or at least is not coupled
to Ca2+channels in the same way as the δ-opioid recep-
tors that arrive via the regulated pathway. This is a
puzzling result that begs further analysis. It would be
of interest, for example, to assess the effect of δ-opioid
receptor agonists on Ca2+channel function in sensory
neurons taken from PPT-A mutant mice.
There is another very important paradox concerning
the function of δ-opioid receptors in the plasma mem-
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498brane. In a previous study, this group reported that
δ-opioid receptor agonists stimulate movement of
LDCVs to the plasma membrane, via an increase in in-
tracellular calcium ions, and that this results in exo-
cytosis of the LDCV and release of its peptide contents
(Bao et al., 2003). Because the peptide content is
largely pronociceptive (pain enhancing), the authors
conclude that the treatment of pain might be improved
by administering a δ-opioid receptor antagonist. How
can these observations be made concordant with the
fact that a δ-opioid receptor agonist is analgesic in
wild-type animals? Perhaps a δ-opioid receptor agonist
concurrently evokes release of pronociceptive media-
tors while inhibiting their release over a longer time
course.
The complexity of δ-opioid receptor activity is further
illustrated by the observation that the efficacy of mor-
phine, which acts via the  subtype of opioid receptor,
is enhanced in the PPT-A mutant mice (Guan et al.
2005). Moreover, the tolerance that normally occurs
with repeated morphine treatment was lost, consistent
with the idea that action at the δ-opioid receptor is, if
anything, pronociceptive. Is it possible that the consti-
tutive and regulated pathways for trafficking of δ-opioid
receptors have opposing functions? Finally, because
chronic morphine treatment can itself influence the traf-
ficking of the δ-opioid receptor to the plasma mem-
brane (Cahill et al., 2001), determining the basis for
morphine’s effects in PPT-A mutant mice may be par-
ticularly difficult.
In addition to raising these and other important phys-
iological questions, the Guan et al. (2005) study prompts
one to consider the generality of this new phenomenon
of coupled peptide-receptor trafficking. For example,
the LDCVs that contain substance P and the δ-opioid
receptor also carry the 5-HT1D subtype of G protein-
linked receptors that respond to serotonin (Potrebic et
al., 2003). Are there a variety of peptide-receptor com-
binations that promote copackaging into LDCVs, and
do these interactions represent private or shared pro-
tein sorting pathways? Future investigations that follow
up on these fascinating cell biological observations
may reveal unexpected mechanisms of membrane traf-
ficking and their relationship to pain, analgesia, and a
host of other physiological processes.
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